literature

HIV mutation literature information.

Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.

PMID: 27124362 2016 Journal of acquired immune deficiency syndromes (1999)

Introduction: A partial list of NNRTI resistance mutations include: L100I, K103N, V106A, E138K, Y181C, Y188L, and H221Y; these mutations can occur singly, or in combinations.

Result: As expected, L234I (6.8 +- 2.5 nM) showed a modest reduction in susceptibility to DOR, while V106A showed a greater loss of susceptibility (15.6 +- 4 nM).

Result: In addition, the triple mutant V106A/

HIV-1 Drug Resistance by Ultra-Deep Sequencing Following Short Course Zidovudine, Single-Dose Nevirapine, and Single-Dose Tenofovir with Emtricitabine for Prevention of Mother-to-Child Transmission.

PMID: 27327263 2016 Journal of acquired immune deficiency syndromes (1999)

Result: Of all mutations conferring resistance to NNRTIs, the most common were those conferring high-level NNRTI resistance such as K103N in 8 of 26 (30%), V106M in 8 of 26 (30%), Y188C in 6 of 26 (23%), G190A in 4 of 26 (15%), Y181C in 3 of 26 (11%), and V106A in 3 of 26 (11%) patients.

Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.

PMID: 27231099 2016 Journal of the International AIDS Society

Table: V106A

Design, Synthesis, and Evaluation of Thiophene[3,2-d]pyrimidine Derivatives as HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Significantly Improved Drug Resistance Profiles.

PMID: 27541578 2016 Journal of medicinal chemistry

Abstract: Compound 27 was the most potent; compared with ETV, its antiviral efficacy was 3-fold greater against WT, 5-7-fold greater against Y181C, Y188L, E138K, and F227L+V106A, and nearly equipotent against L100I and K103N, though somewhat weaker against K103N+Y181C.

Genotypic HIV-1 Drug Resistance Among Patients Failing Tenofovir-Based First-Line HAART in South India.

PMID: 27334566 2016 AIDS research and human retroviruses

Abstract: The predominant NRTI and NNRTI mutations observed were M184IV (59.9%), K65R (28.1%), and thymidine analogue mutations (TAMs, 29.3%) and K103NS (54.5%), V106AM (39.5%), and Y181CIV (19.8%), respectively.

Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia.

PMID: 25754408 2015 Journal of medical virology

Result: The most prevalent NNRTI mutations were Y181C/I/V (n = 24, 35%), (n = 3, 4%), and (n = 1 (1%), respectively, K103N/S (n = 21 (32%) and n = 1 [1%]), G190A/S/E (n = 20 (29%), n = 1 (1%), and (n = 2, 3%), respectively, V108I (n = 13, 19%), and V106A/M (n = 2, 3%) and (n = 10, 15%).

The prevalence and determinants of drug-resistance-associated mutations in the HIV-1-infected MSM population of Henan Province in China.

PMID: 26077516 2015 Archives of virology

Abstract: After antiretroviral therapy (ART), the frequencies of K103N, G190A, Y181C, and V106A mutations were highly elevated.

High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau.

PMID: 25889017 2015 Virology journal

Table: V106A

Mutations in the reverse transcriptase and protease genes of human immunodeficiency virus-1 from antiretroviral naive and treated pediatric patients.

PMID: 25674767 2015 Viruses

Table: V106A

Discussion: Two ART naive patients, AIIMSU63 and AIIMSPD5 harbored L74I (conferring high level of resistance to didanosine; NNRTI inhibitor) and V106A (conferring high level of resistance to nevirapine; NNRTI inhibitors) mutations respectively.

In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.

PMID: 25482475 2015 AIDS research and human retroviruses

Abstract: Initial mutations, in combination with other previously reported substitutions (K20R, D67N, V90I, K101R/E, V106I/A, V108I, F116L, E138R, A139V, V189I, G190A, D218E, E203K, H221Y, F227L, N348I, and T369I) or novel mutations (V8I, S134N, C162Y, L228I

Browser Board

Co-occurred Entities

Filtrator